文献速递妇科

错配修复缺陷在子宫内膜样子宫内膜癌中的临床意义:前瞻性研究

Understanding the clinical implication of mismatch repair deficiency in endometrioid endometrial cancer through a prospective study.
PubMed 文献 · Gynecol Oncol · 2021-01-19

该前瞻性研究纳入加拿大安大略省三个癌症中心2015至2018年492例子宫内膜样子宫内膜癌(EEC)病例,通过免疫组化反射性检测错配修复(MMR)蛋白表达,比较MMRd与MMRi的肿瘤学结局和复发模式。结果显示MMRd肿瘤更具侵袭性特征且3年无复发生存率更低,其中MLH1甲基化肿瘤预后最差。

要点

  • MMRd在EEC中占29%,更常见于2-3级、淋巴血管间隙浸润和淋巴结受累。
  • MMRd组3年无复发生存率显著低于MMRi组(78% vs. 90%,p=0.014),但总生存无差异。
  • MLH1甲基化EEC具有最差的预后特征和生存结局,提示需按分子表型个体化管理。

核心结论

  • MLH1甲基化EEC相比其他MMRd和MMRi EEC表现出更具侵袭性的特征和更差的生存结局,提示肿瘤生物学存在内在差异,基于EC分子表型的个体化管理具有重要意义。

研究设计与样本

  • 前瞻性研究,2015至2018年从加拿大安大略省三个癌症中心招募492例子宫内膜样子宫内膜癌(EEC)病例,通过免疫组化反射性评估MMR蛋白表达,比较MMRd与MMRi的临床病理、生存和复发模式。

主要发现

  • 492例EEC中,MMRi 348例(71%),MMRd 144例(29%),中位随访16.8个月(0-69.6)。
  • MMRd肿瘤更多为2或3级(56% vs. 29%,p < 0.001),更易发生淋巴血管间隙浸润(28% vs. 18%,p = 0.024)和淋巴结受累(7% vs. 5%,p < 0.001),接受更多辅助治疗(46% vs. 33%,p = 0.027)。
  • MMRd组3年无复发生存率显著更低(78% vs. 90%,p = 0.014),但总生存无差异(p = 0.603)。
  • MMRd病例更倾向于腹膜后淋巴结复发(p = 0.045)。
  • 亚组分析显示MLH1甲基化肿瘤具有最差的预后特征和生存结局。

临床怎么用

  • 对EEC进行MMR免疫组化检测有助于识别MMRd亚型,其更具侵袭性特征且复发风险更高。
  • MLH1甲基化EEC预后最差,提示应基于分子表型考虑个体化辅助治疗和随访策略。

局限性

  • 中位随访时间较短(16.8个月),可能影响长期生存结局的评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Findings on impact of mismatch repair deficiency (MMRd) on patient outcomes in endometrial cancer (EC) have been inconsistent to date. The objective of this study was to compare the oncologic outcomes and recurrence patterns between MMRd and MMR-intact (MMRi) endometrioid EC (EEC). METHODS: Between 2015 and 2018, we prospectively recruited 492 EEC cases from three cancer centers in Ontario, Canada. Tumors were reflexively assessed for MMR protein expression by immunohistochemistry (IHC). Clinicopathological, survival and recurrence patterns were compared between MMRd and MMRi cases. RESULTS: Of 492 EEC, 348 were MMRi (71%) and 144 were MMRd (29%) with median follow-up of 16.8 months (0-69.6). MMRd tumors tended to be grade 2 or 3 (56% vs. 29%, p < 0.001), with propensity for lymphovascular space invasion (28% vs. 18%, p = 0.024), lymph node involvement (7% vs. 5%, p < 0.001) and received more adjuvant treatment (46% vs. 33%, p = 0.027). This group also had significantly lower 3-year recurrence-free survival (78% vs. 90%, p = 0.014) although there was no difference in OS (p = 0.603). MMRd cases were more likely to recur in retroperitoneal lymph nodes (p = 0.045). Upon subgroup analysis, MLH1 methylated tumors had the worst prognostic features and survival outcomes. CONCLUSIONS: MLH1 methylated EECs exhibit more aggressive features compared to other MMRd and MMRi EECs. This may indicate an inherent difference in tumor biology, suggesting the importance of individualized management based on EC molecular phenotype.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Kim SR, Tone A, Kim RH, et al. Understanding the clinical implication of mismatch repair deficiency in endometrioid endometrial cancer through a prospective study. Gynecol Oncol. 2021. PMID: 33478752. doi:10.1016/j.ygyno.2021.01.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。